Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI
Conclusion: These findings provide information about biomarker enrichment and outcome measurements that could be employed to reduce MCI patient samples and treatment duration in future clinical trials.
Source: Alzheimer Disease and Associated Disorders - Category: Geriatrics Tags: Original Articles Source Type: research
More News: Alzheimer's | Clinical Trials | Geriatrics | MRI Scan | Neurology | PET Scan | Statistics | Study